R-Bambuterol Hydrochloride is categorized as a Class I new drug. In preclinical studies, R-Bambuterol Hydrochloride demonstrated a promising efficacy and safety profile. Obtaining permission from the SFDA Ethics
Novartis plans to expand its current Massachusetts Avenue campus, adjacent to MIT, by more than 400,000 sft, including laboratory, office and retail space. Construction is expected to begin
The three-year project ‘Disease-modifying drug discovery in cystic fibrosis’ focuses on Galapagos’ CF program based on new drug targets, with the goal to deliver a pre-clinical candidate. Galapagos
Eisai obtained the exclusive rights to develop and market KES524 in Japan in an agreement with Abbott. Eisai had submitted a MAA for the agent to the Japanese
HGS has posted a net loss of $40.86m for the third quarter 2010, or $0.22 loss per diluted share, compared to net loss of $49m, or $0.32 loss
The agreement grants Jingxin Pharma exclusive rights to develop and market EVT 201 in China. Evotec is expected to receive a small upfront payment, together with commercial milestones
B Braun was recently notified by its supplier, Scientific Protein Laboratories LLC (SPL), that an additional testing of retained crude heparin samples used by SPL to manufacture this
Humira exerts its effects by neutralising TNF-alpha, a cytokine that plays a central role in inflammatory responses. The MHLW cleared the condition for approval on the basis of
ViroPharma has posted a net income of $38.34m for the third quarter 2010, or $0.45 per diluted share, compared to $20.07m, or $0.24 per diluted share, for the
Prior to joining Cenergy, Thomas served as COO of Engineered Sports Technology (EST), where he was successful in building relationships with raw material manufacturers as well as upper-level
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.